Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Short-term Investments (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Short-term Investments readings, the most recent being $767.4 million for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 8.98% to $767.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $767.4 million, a 8.98% decrease, with the full-year FY2025 number at $767.4 million, down 8.98% from a year prior.
  • Short-term Investments hit $767.4 million in Q4 2025 for Neurocrine Biosciences, down from $774.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $899.2 million in Q2 2024 to a low of $370.5 million in Q4 2021.
  • Median Short-term Investments over the past 5 years was $758.4 million (2025), compared with a mean of $684.2 million.
  • Biggest five-year swings in Short-term Investments: tumbled 39.65% in 2021 and later skyrocketed 100.35% in 2023.
  • Neurocrine Biosciences' Short-term Investments stood at $370.5 million in 2021, then surged by 96.06% to $726.4 million in 2022, then grew by 7.45% to $780.5 million in 2023, then rose by 8.02% to $843.1 million in 2024, then fell by 8.98% to $767.4 million in 2025.
  • The last three reported values for Short-term Investments were $767.4 million (Q4 2025), $774.6 million (Q3 2025), and $711.6 million (Q2 2025) per Business Quant data.